CN115484966A - 治疗和预防植入性心律失常的方法 - Google Patents

治疗和预防植入性心律失常的方法 Download PDF

Info

Publication number
CN115484966A
CN115484966A CN202180027573.1A CN202180027573A CN115484966A CN 115484966 A CN115484966 A CN 115484966A CN 202180027573 A CN202180027573 A CN 202180027573A CN 115484966 A CN115484966 A CN 115484966A
Authority
CN
China
Prior art keywords
amiodarone
administration
ivabradine
cardiomyocytes
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027573.1A
Other languages
English (en)
Chinese (zh)
Inventor
比约恩·科诺尔曼
罗伯特·斯科特·蒂斯
威廉·罗伯特·梅克莱兰
肯塔·纳卡穆拉
查尔斯·E·莫里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WASHINGTON, University of
Vanderbilt University
Original Assignee
WASHINGTON, University of
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WASHINGTON, University of, Vanderbilt University filed Critical WASHINGTON, University of
Publication of CN115484966A publication Critical patent/CN115484966A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180027573.1A 2020-02-10 2021-02-09 治疗和预防植入性心律失常的方法 Pending CN115484966A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062972330P 2020-02-10 2020-02-10
US62/972,330 2020-02-10
PCT/US2021/017220 WO2021163037A1 (en) 2020-02-10 2021-02-09 Methods of treating and preventing engraftment arrhythmias

Publications (1)

Publication Number Publication Date
CN115484966A true CN115484966A (zh) 2022-12-16

Family

ID=77291628

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027573.1A Pending CN115484966A (zh) 2020-02-10 2021-02-09 治疗和预防植入性心律失常的方法

Country Status (11)

Country Link
US (1) US20230077983A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103206A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023512843A (cg-RX-API-DMAC7.html)
KR (1) KR20220140532A (cg-RX-API-DMAC7.html)
CN (1) CN115484966A (cg-RX-API-DMAC7.html)
AU (1) AU2021218653A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015768A2 (cg-RX-API-DMAC7.html)
CA (1) CA3166678A1 (cg-RX-API-DMAC7.html)
IL (1) IL295236A (cg-RX-API-DMAC7.html)
MX (1) MX2022009807A (cg-RX-API-DMAC7.html)
WO (1) WO2021163037A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3979997A1 (en) * 2019-06-06 2022-04-13 Novo Nordisk A/S Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof
US20230250393A1 (en) * 2022-02-09 2023-08-10 University Of Washington Pre-treating cardiomyocytes with anti-arrhythmic drugs to reduce engraftment arrhythmia
WO2023173123A1 (en) * 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
JP2025532951A (ja) * 2022-09-28 2025-10-03 ブルーロック・セラピューティクス・リミテッド・パートナーシップ 移植関連不整脈を処置するための組成物および方法
AU2024406171A1 (en) * 2023-12-22 2026-06-18 Bluerock Therapeutics Lp Molecular identification of cardiomyocytes for cardiac cell therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151755A1 (en) * 2012-04-04 2013-10-10 University Of Washington Through Its Center For Commercialization Systems and method for engineering muscle tissue
US20140363841A1 (en) * 2012-01-20 2014-12-11 Singapore Health Services Pte Ltd Induced pluripotent stem cell (ipsc)-derived cardiomyocyte-like cells and uses thereof
WO2016176333A1 (en) * 2015-04-27 2016-11-03 Reflex Medical, Inc. Systems and mehtods for sympathetic cardiopulmonary neuromodulation
WO2018170280A1 (en) * 2017-03-15 2018-09-20 University Of Washington Methods and compositions for enhancing cardiomyocyte maturation and engraftment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3979997A1 (en) * 2019-06-06 2022-04-13 Novo Nordisk A/S Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140363841A1 (en) * 2012-01-20 2014-12-11 Singapore Health Services Pte Ltd Induced pluripotent stem cell (ipsc)-derived cardiomyocyte-like cells and uses thereof
WO2013151755A1 (en) * 2012-04-04 2013-10-10 University Of Washington Through Its Center For Commercialization Systems and method for engineering muscle tissue
WO2016176333A1 (en) * 2015-04-27 2016-11-03 Reflex Medical, Inc. Systems and mehtods for sympathetic cardiopulmonary neuromodulation
WO2018170280A1 (en) * 2017-03-15 2018-09-20 University Of Washington Methods and compositions for enhancing cardiomyocyte maturation and engraftment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JANA-KATHARINA DIEKS等: "Adjunctive ivabradine in combination with amiodarone: A novel therapy for pediatric congenital junctional ectopic tachycardia", HEART RHYTHM., vol. 13, no. 6, 30 June 2016 (2016-06-30), pages 2 - 3 *
KAZUNORI UEMURA等: "Acute ivabradine treatment reduces heart rate without increasing atrial fibrillation inducibility irrespective of underlying vagal activity in dogs", HEART VESSELS, 14 November 2016 (2016-11-14), pages 1 *
YEN-WEN LIU等: "Human ESC-Derived Cardiomyocytes Restore Function in Infarcted Hearts of Non-Human Primates", NAT BIOTECHNOL., vol. 37, no. 7, 31 August 2018 (2018-08-31), pages 4 *

Also Published As

Publication number Publication date
AU2021218653A1 (en) 2022-09-01
JP2023512843A (ja) 2023-03-29
CA3166678A1 (en) 2021-08-19
BR112022015768A2 (pt) 2022-11-22
KR20220140532A (ko) 2022-10-18
WO2021163037A1 (en) 2021-08-19
EP4103206A1 (en) 2022-12-21
IL295236A (en) 2022-10-01
EP4103206A4 (en) 2024-03-13
MX2022009807A (es) 2022-11-10
US20230077983A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
US20230077983A1 (en) Methods of treating and preventing engraftment arrhythmias
Biressi et al. Stem cell therapy for muscular dystrophies
KR101920891B1 (ko) 심장 치료를 위한 골수 유래 cd271 전구 세포
JP7091427B2 (ja) 心不全の治療方法
EP3556378A1 (en) Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
EP3595679A1 (en) Methods and compositions for enhancing cardiomyocyte maturation and engraftment
JP2012518041A (ja) 心不整脈を予防するための組成物および方法
Dariolli et al. Allogeneic pASC transplantation in humanized pigs attenuates cardiac remodeling post-myocardial infarction
US20160015860A1 (en) Micro-tissue particles and methods for their use in cell therapy
Schoenfeld et al. The existence of myocardial repair: mechanistic insights and enhancements
Johnston et al. Dare to dream? Cell-based therapies for heart failure after DREAM-HF: Review and roadmap for future clinical study
US8889122B2 (en) Cellular cardiomyoplasty as supportive therapy in patients with heart disease
US20230250393A1 (en) Pre-treating cardiomyocytes with anti-arrhythmic drugs to reduce engraftment arrhythmia
Spaltro et al. Physiological conditions influencing regenerative potential of stem cells
Rheault-Henry et al. Therapeutic Uses of Stem Cells for Heart Failure: Hype or Hope
Gómez Cid Development, characterization and evaluation of advanced therapies for the treatment of cardiac pathologies
Rheault-Henry et al. Unraveling the Mystery of Regenerative Medicine in the Treatment of Heart Failure
Akar et al. Failing heart; remodel, replace or repair?/Terminal dönem kalp yetersizligi: Kalp nakli mi? Yeniden biçimlendirme mi? Yoksa onarim mi?
Garcia Analysis of the regenerative potential of the induced pluripotent stem cells in a model of acute myocardial infarction in mice
CN121586768A (zh) 心肌细胞群、药物组合物、制备心肌细胞群的方法和心肌细胞球体
WO2015006510A1 (en) Methods for treating an established myocardial infarction
Nakamura et al. Article Pharmacologic therapy for engraftment arrhythmia induced by transplantation of human cardiomyocytes
Rodrigo Intramyocardial bone marrow cell injection for ischemic heart disease: efficacy
Noiseux et al. STEM CELLS THERAPY FOR ISCHEMIC CARDIOVASCULAR DISEASES: NEW INSIGHTS ON MECHANISMS AND FATE OF THE IMPLANTED CELLS
Al-Nbaheen Mesenchymal Stromal Cells in Cardiovascular Disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination